Considerable progress has been made in recent years understanding the underlying molecular basis for blood vessel formation and maturation. How endothelial cells form tubes and sprout and how they attract mural cells to create mature blood vessels has been investigated and reviewed extensively. In contrast, very little work has focused on the converse of vessel formation, which is the molecular basis for vessel regression. A molecular understanding of vessel regression may lead to new therapeutic opportunities in many clinical contexts where capillary regression has been implicated as a key pathogenic feature. Capillary loss or rarefaction is observed in major human diseases including ischemia and infarction, hypertension, diabetes, malignant cancer, neurodegenerative diseases and wound repair responses. In addition, capillary regression plays a role in physiologic contexts including hyaloid vessel regression, and the menstrual cycle. Capillary regression mechanisms that occurred secondary to degradation of the extracellular matrix environment in which capillaries are embedded through the action of matrix metalloproteinases (MMPs) (e.g. MMP-1 and MMP-10) and MMP activators including serine proteinases such as plasmin have been previously investigated.
Pro-inflammatory mediators are known to have a profound influence on the vasculature and cause increased vascular permeability, leukocyte adhesion and transmigration, increased pro-coagulant activities, and increased platelet adhesion and aggregation. Key mediators include interleukin-1 (IL-1), tumor necrosis factor (TNF), and thrombin as well as many other cytokines and small molecule mediators that regulate these processes in health and disease states. Many recent studies indicate the therapeutic benefits in humans of neutralizing antibodies or pharmacologic antagonists directed to interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and thrombin in key disease states including atherosclerosis, pro-inflammatory diseases (e.g. arthritis, Crohn's disease, psoriasis), pro-thrombotic diseases (e.g. deep venous thrombosis, pulmonary embolism), and malignant cancer.
In some embodiments, presented herein are methods of treating a disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an inhibitor of capillary tube regression.
In some embodiments, presented herein are methods for treating a disease, the method comprising administering to a patient identified or diagnosed as having capillary tube regression a therapeutically effective amount of an inhibitor of capillary tube regression.
In some embodiments, presented herein are methods of treating a disease in a patient, the method comprising: a) confirming the presence of capillary tube regression in the patient; and b) administering to the patient a therapeutically effective amount of an inhibitor of capillary tube regression.
In some embodiments, presented herein are methods of treating a disease in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of lymphatic tube regression.
In some embodiments, presented herein are methods of treating a disease, the method comprising administering to a patient identified or diagnosed as having capillary tube regression a therapeutically effective amount of an inhibitor of lymphatic tube regression.
In some embodiments, presented herein are methods of treating a disease in a patient, the method comprising: c) confirming the presence of lymphatic tube regression in the patient; and d) administering to the patient a therapeutically effective amount of an inhibitor of lymphatic tube regression.
In some embodiments, presented herein are methods of the above, wherein the disease comprises ischemia, infarction, hypertension, diabetes, malignant cancer, neurodegenerative disease, wound repair response, atherosclerosis, pro-inflammatory disease, pro-thrombotic disease, viral infection, bacterial infection, and any combination thereof. In some embodiments, the pro-inflammatory disease comprises arthritis, Crohn's disease, psoriasis, and any combination thereof. In some embodiments, the viral infection is a SARS-CoV-2 infection, influenza, or any combination thereof. In some embodiments, the pro-thrombotic disease comprises deep vein thrombosis, pulmonary embolism, and any combination thereof. In some embodiments, the inhibitor is a pharmacologic agent. In some embodiments, the pharmacologic agent is a small molecule. In some embodiments, the small molecule comprises a chemical compound. In some embodiments, the inhibitor comprises forskolin, IBMX, SB239, tubacin, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239, tubacin, or any combination thereof 16. The method of any one of claims 1 to 10, wherein the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, SB431542, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, SB431542, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB SB239063239, tubacin, K02288, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, K02288, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, TCS-HDAC6, tubastatin, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, TCS-HDAC6, tubastatin, SB415286, or any combination thereof.
In some embodiments, the inhibitor comprises an antibody. In some embodiments, the antibody comprises a neutralizing antibody. In some embodiments, the antibody comprises an antibody directed to IL-10, TNFα, or any combination thereof. In some embodiments, the inhibitor is an inhibitor of thrombin generation. In some embodiments, the inhibitor of thrombin generation is a Factor Xa inhibitor, a PAR1 inhibitor, or any combination thereof. In some embodiments, the inhibitor comprises a pharmacologic agent, an antibody, an inhibitor of thrombin generation, or any combination thereof.
In some embodiments, presented herein are pharmaceutical compositions comprising an inhibitor of capillary regression. In some embodiments, the capillary is a blood-carrying capillary, a lymphatic capillary, or any combination thereof. In some embodiments, the inhibitor of the pharmaceutical composition is a pharmacologic agent. In some embodiments, the pharmacologic agent is a small molecule. In some embodiments, the small molecule comprises a chemical compound. In some embodiments, the inhibitor comprises forskolin, IBMX, SB239, tubacin, SB415286, an inhibitor of thrombin generation, or any combination thereof. In some embodiments, the inhibitor of thrombin generation comprises a Factor Xa inhibitor, a PAR1 inhibitor, or any combination thereof. In some embodiments, the inhibitor comprises forskolin, IBMX, SB239063, tubacin, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises forskolin, IBMX, SB239063, tubacin, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, SB431542, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, SB431542, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, K02288, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, K02288, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, TCS-HDAC6, tubastatin, or any combination thereof. In some embodiments, the inhibitor comprises, forskolin, IBMX, SB239063, tubacin, TCS-HDAC6, tubastatin, SB415286, or any combination thereof. In some embodiments, the inhibitor comprises an antibody. In some embodiments, the antibody comprises a neutralizing antibody. In some embodiments, the antibody comprises an antibody directed to IL-10, TNFα, or any combination thereof.
In some embodiments presented herein are pharmaceutical compositions comprising a pharmacologic agent and an antibody. In some embodiments, the pharmacologic agent comprises forskolin, IBMX, SB239063, tubacin, SB415286, an ALK inhibitor, an inhibitor of thrombin generation, or any combination thereof. In some embodiments, the antibody comprises an antibody directed to IL-10, TNFα, or any combination thereof.
In some embodiments, presented herein are pharmaceutical compositions for use in the treatment of a disease in a patient in need thereof. In some embodiments, the pharmaceutical compositions comprise an inhibitor of capillary tube regression. In some embodiments, the pharmaceutical compositions comprise a therapeutically effective amount of the inhibitor of capillary tube regression. In some embodiments, the pharmaceutical compositions comprise an inhibitor of lymphatic tube regression. In some embodiments, the pharmaceutical compositions comprise a therapeutically effective amount of the inhibitor of lymphatic tube regression. In some embodiments, presented herein are pharmaceutical compositions for use in the treatment of a pro-inflammatory disease in a patient in need thereof. In some embodiments, presented herein are pharmaceutical compositions for use in the treatment of a pro-thrombotic disease in a patient in need thereof. In some embodiments, presented herein are pharmaceutical compositions for use in the treatment of a viral infection in a patient in need thereof. In some embodiments, presented herein are pharmaceutical compositions for use in the treatment of a bacterial infection in a patient in need thereof. In some embodiments, presented herein are pharmaceutical compositions for use in the treatment of COVID-19 in a patient in need thereof.
The following drawings illustrate certain embodiments of the features and advantages of this disclosure. These embodiments are not intended to limit the scope of the appended claims in any manner. Like reference symbols in the drawings indicate like elements.
Detailed herein are compositions and methods of treatment for inhibiting capillary tube regression and/or lymphatic tube network regression. In some embodiments, factors and signaling pathways that control the regression of capillary tube networks are also described herein. In some embodiments, a detailed screen of growth factors, and cytokines as well as the inflammatory mediator, thrombin, can be used to identify IL-1, TNFα and thrombin (and these mediators in combination), as markedly causing endothelial cell (EC) tube collapse and EC apoptosis over a period of time. In some embodiments, this period of time is between about 24 to about 48 hours. In some embodiments, these pro-regressive mediators selectively induce the regression of EC-lined tube networks with EC cell death, while associated pericytes are spared and proliferate in response. In some embodiments, pro-inflammatory macrophages which can be activated by the TLR agonists, Pam3CSK4 or LPS, produced potent pro-regressive activities. In some embodiments, these pro-regressive activities were identified as IL-1β and TNFα. In some embodiments, other pro-regressive factors were identified. In some embodiments, these other pro-regressive activities had a potency level at the potency level of IL-1β and TNFα (e.g., IL-la). In some embodiments, these other pro-regressive activities had a potency level below the potency level of IL-10 and TNFα. In some embodiments, thrombin, which is often co-generated in tissue injury responses along with cytokines such as IL-10 and TNFα, further enhances the pro-regressive activity of these cytokines individually or when they are combined. In some embodiments, the pro-inflammatory cytokines, IL-10 and TNFα, in conjunction with thrombin are the major factors that promote capillary tube regression. In some embodiments, the pro-inflammatory cytokines, IL-1β, IL-la, TNFα, in conjunction with thrombin are the major factors that promote capillary tube regression. In some embodiments, thrombin enhances the pro-regressive activities of both IL-1 isoforms and TNFα. In some embodiments, in serious tissue injury contexts, all three of these pro-regressive molecules will be present (e.g., in a “cytokine storm”), and thus, it can be necessary to inhibit them in combination to interfere with capillary regression responses. In some embodiments, capillary regression can be a pathogenic factor in human diseases. Non-limiting examples of human diseases where capillary regression can be a pathogenic factor can include ischemia and infarction, diabetes, hypertension, neurodegenerative diseases, malignant cancers, heart failure, sepsis, coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), a viral infection or viral infectious disease, and a bacterial infection or bacterial infectious disease. In some embodiments, the viral infection is a SARS-CoV-2 infection, a coronavirus infection, a rhinovirus infection, an adenovirus infection. In some embodiments, the viral infectious disease is influenza, COVID-19, or pneumonia. In some embodiments, neutralizing antibodies to TNFα and IL-1β as well as chemical inhibitors that block thrombin generation (e.g., Factor Xa inhibitors and/or protease-activated receptor 1 (PAR1) inhibitors) can provide a therapeutic strategy in these clinical situations.
In some embodiments, in severe cases, COVID-19 is associated with acute respiratory distress syndrome (ARDS), which classically results from increased permeability of pulmonary capillaries. In some embodiments, the vascular leakage characteristic of ARDS diminishes the capacity for oxygen to diffuse from the alveolar space into adjacent capillaries, leading to respiratory failure and systemic hypoxia. In some embodiments, other mechanisms that can contribute to capillary dysfunction and hypoxia include development of microthrombi and endothelial cell (EC) death. In some embodiments, COVID-19 patients exhibit pulmonary capillary damage, including microthrombi, inflammatory cell infiltration into small vessels, EC death, edema, and focal hemorrhages. In some embodiments, COVID-19 might lead to EC death and capillary regression in lungs and other organs, resulting in an ARDS-like condition, systemic hypoxia and multi-organ failure.
In some embodiments, patients with particularly severe COVID-19 symptoms frequently show marked elevation of pro-inflammatory factors such as thrombin, interferon gamma (IFNγ), and the cytokines TNFα, IL-6, and IL-1β. In some embodiments, thrombin, IFNγ, TNFα, IL-6, and IL-1β can cause vascular permeability and/or thrombosis in a COVID-19 patient. In some embodiments, thrombin, IFNγ, TNFα, IL-6, IL-1β, and any combination thereof can cause vascular damage in a COVID-19 patient. In some embodiments, IFNγ and interleukin-4 (IL-4) can have a strong pro-regressive activity. In some embodiments, IFNγ and IL-4 can be upregulated factors in the “cytokine storm” exhibited by COVID-19 patients.
In some embodiments, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can induce capillary regression in infected tissues such as the lung and heart, which are essential for systemic oxygenation and tissue health. In some embodiments, macrophages are a major source of inflammatory cytokines, including the ones that can trigger capillary regression. In some embodiments, SARS-coronaviruses and other highly pathogenic viruses can activate the NLRP3 inflammasome, which leads to production and release of IL-1β and IL-18 from various cell types, including macrophages. Therefore, in some embodiments, direct infection of macrophages with SARS-CoV-2, or interactions between macrophages and other infected cell types (e.g., in the alveolar wall), can induce inflammasome activation and local elevation of active IL-10 as well as upregulate the production and release of other key mediators such as TNFα and thrombin that could drive capillary regression.
In some embodiments, identifying a capillary regression signaling signature can help determine if capillary regression is occurring in COVID-19 patients. In some embodiments, the capillary regression signaling signature includes increased levels of phospho-p38 Map kinase, phospho-MLC2, and/or an induction of ICAM-1 compared to basal levels (e.g., of a healthy patient or an uninfected patient). In some embodiments, the capillary regression signaling signature includes decreased levels of phospho-Pak2, phospho-cofilin, acetylated tubulin, and/or pro-caspase3 compared to basal levels (e.g., of a healthy patient or an uninfected patient). In some embodiments, the severity of the COVID-19 in a patient can relate to the extent of capillary loss during the infection coupled to the basal state of pulmonary capillary density and function that was present in the patient prior to viral infection, as shown in
In some embodiments, the combination of TNFα and thrombin, but not IL-1β, can cause marked regression of lymphatic tube networks. In some embodiments, pro-inflammatory mediators can cause regression of blood-carrying capillary tubes, and also regression of lymphatic tube networks. In some embodiments, these latter lymphatic networks remove pro-inflammatory mediators from tissue injury sites. Thus, in some embodiments, these mediators can persist in these injured sites due to loss of lymphatic capillaries, which might further induce blood-carrying capillary regression. In some embodiments, the development of capillary protection agents can be used to prevent the regression of both blood containing capillaries as well as lymphatic capillaries.
In some embodiments, IL-1β, IL-la, and TNFα can be potent regulators of capillary tube regression. In some embodiments, pro-inflammatory macrophages can produce pro-regressive factors for capillary networks. In some embodiments, macrophages (e.g., human macrophages) exposed to TLR ligands can induce pro-regressive activity as compared to a non-exposed control. Non-limiting examples of TLR ligands can include Pam3CSK4 and LPS. In some embodiments, Pam3CSK4 and LPS are added to the macrophages in combination at the same time. In some embodiments, Pam3CSK4 and LPS are added to the macrophages in combination at different times. In some embodiments, addition of either TLR ligand itself to EC tube networks does not influence capillary regression. In some embodiments, Pam3CSK4- and LPS-induced macrophage media pro-regressive activity can be blocked by a combination of antibodies directed to both IL-1β and TNFα. In some embodiments, neutralizing antibodies directed to other less potent pro-regressive growth factors and cytokines do not block the influence of the macrophage conditioned medium.
In some embodiments, physiologic capillary regression can be modeled in a mouse by examining the postnatal regression of the eye hyaloid vasculature. In some embodiments, this vascular regressive response can depend on the presence of adjacent macrophages which decorate this developmental vascular bed. In some embodiments, intraocular administration of blocking antibodies to TNFα and IL-1β in combination, as compared to a vehicle control, reduced the hyaloid regression response. In some embodiments, injection of the anti-inflammatory cytokine, IL-10 (which is known to decrease TNFα and IL-1β expression), also inhibited hyaloid regression. In some embodiments, EC capillary regression during hyaloid regression can include increased expression of ICAM-1 (at the mRNA and protein level) and increased presence of phospho-MLC2 in regressing hyaloid ECs.
In some embodiments, IL-1β, TNFα, and thrombin, selectively induce EC tube regression but pericytes, despite their assembly on the abluminal surface of the regressing tubes, remain intact and proliferate in response to the pro-regressive factors. In some embodiments, pericytes do not decline and regress under EC tube regression by IL-1β, TNFα, and thrombin. In some embodiments, cellular pathways activated during regression induced with IL-1β and TNFα treatment as well as with macrophage conditioned medium can include increased phospho-p38 Map kinase, phospho-MLC2, and induction of ICAM-1. In some embodiments, pathways that are inactivated during regression induced with IL-1β and TNFα treatment as well as with macrophage conditioned medium can include decreased levels of phospho-Pak2, phospho-cofilin, acetylated tubulin and procaspase3. In some embodiments, the activation is accentuated when thrombin is added to IL-1β or TNFα. In some embodiments, the inactivation is accentuated when thrombin is added to IL-1β or TNFα.
In some embodiments, pharmacologic agents (e.g., inhibitors or agonists) can prevent EC tube regression events. In some embodiments, pharmacologic agents (e.g., inhibitors or agonists) can prevent lymphatic tube regression events. In some embodiments, pharmacologic agents (e.g., inhibitors or agonists) can prevent EC tube regression events, EC death, and/or lymphatic tube regression occurring in an infected patient (e.g., infected by SARS-CoV-2, influenza, or bacteria). In some embodiments, pharmacologic agents (e.g., inhibitors or agonists) can prevent EC tube regression events, EC death, and/or lymphatic tube regression caused by an infection (e.g., a SARS-CoV-2 infection, influenza, or bacterial infection). In some embodiments, pharmacologic agent combinations can rescue back to control levels or above the EC tube regression, EC death, and/or lymphatic tube regression events induced by the pro-regressive factors and their combinations described herein. In some embodiments, a reduction of EC tube regression by about 100%, about 98%, about 96%, about 94%, about 92%, about 90%, about 88%, about 86%, about 84%, about 82%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, or any value between indicates rescue of the pro-regressive factors and there combinations.
In some embodiments, the pharmacologic agent combination can include agents involved in stimulating cyclic AMP levels, inhibiting p38 Map kinases, inhibiting tubulin or histone deacetylase (e.g., HDAC), and inhibiting GSK3(3. In some embodiments, the pharmacologic agent combination can include FIST (e.g., forskolin, IBMX (3-isobutyl-1-methylxanthine), SB239, tubacin). In some embodiments, SB239 is sometimes referred to SB239063. In some embodiments, the pharmacologic agent combination can include FISTSB (e.g., forskolin, IBMX, SB239, tubacin, SB415286). In some embodiments, the capillary regression can have a common signaling mechanism. In some embodiments, FISTSB is more effective, as compared to FIST, at rescuing these factors when they are added in combination. In some embodiments, FISTSB is more effective, as compared to FIST, at rescuing the combinations of IL-1β or TNFα with thrombin. In some embodiments, FISTSB is more effective, as compared to FIST, at rescuing high concentrations of IL-10 and TNFα when added individually, in combination or with thrombin. In some embodiments, the high concentration of IL-10 and TNFα when added individually, in combination or with thrombin can mimic what can occur in serious tissue injury and life-threatening situations where systemic macrophage activation and vascular permeability occur together leading to high levels of IL-1β, TNFα and thrombin. In some embodiments, a high concentration is greater than 1 ng/ml. In some embodiments, a high concentration is greater than 3 ng/ml. In some embodiments, a high concentration is approximately 4 ng/ml, 5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 9 ng/ml, 10 ng/ml, 11 ng/ml, 12 ng/ml, 13 ng/ml, 14 ng/ml, 15 ng/ml, ng/ml, 30 ng/ml, 40 ng/ml, 50 ng/ml, 60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml, 100 ng/ml, or greater. In some embodiments, a high concentration is approximately 10 ng/ml.
In some embodiments, the pharmacologic agent can include an antagonistic recombinant protein that inhibits one or more of the pro-regressive inflammatory mediators disclosed herein. In some embodiments, the antagonistic recombinant protein is interleukin-1 receptor antagonist (IL-1RA). In some embodiments, the pharmacologic agent can include a histone deacetylase (HDAC) inhibitor. In some embodiments, the HDAC inhibitor is a class I, IIA, IIB, III, or IV HDAC inhibitor. In some embodiments, the HDAC inhibitor includes tubastatin, TCS-HDAC6, tubacin, and any combinations thereof. In some embodiments, the pharmacologic agent can include activin receptor-like kinase 4 (ALK4) and/or ALK5 inhibitor. In some embodiments, the pharmacologic agent can include SB431542. In some embodiments, the pharmacologic agent can include ALK2 and/or ALK1 inhibitor. In some embodiments, the pharmacologic agent can include K02288.
In some embodiments, EC capillary regression and/or lymphatic tube regression can be rescued by a combination of pharmacologic agents. In some embodiments, EC capillary regression and/or lymphatic tube regression occurring in an infected patient (e.g., infected by SARS-CoV-2, influenza, or bacteria) can be rescued by a combination of pharmacologic agents. In some embodiments, EC capillary regression and/or lymphatic tube regression caused by an infection (e.g., a SARS-CoV-2, influenza, or bacterial infection) can be rescued by a combination of pharmacologic agents. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an antagonistic recombinant protein, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, IL-1RA, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an HDAC inhibitor, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, tubastatin, TCS-HDAC6, tubacin, or combinations thereof.
Activin receptor-like kinases (ALKs) are receptors in the transforming growth factor beta (TGF-β) signaling pathway. In some embodiments, TGF-β can induce EC tube regression. In some embodiments, TGF-β is a pro-regressive factor. In some embodiments, inhibiting TGF-β, disrupting the TGF-β signaling pathway, or inhibiting an ALK (e.g., ALK4, ALK5, ALK1, and/or ALK2) can reduce, reverse, or prevent EC tube regression. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an ALK4 inhibitor, an ALK5 inhibitor, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, SB431542, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an ALK2 inhibitor, an ALK1 inhibitor, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, K02288, or combinations thereof.
In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, SB431542, K02288, or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, SB431542, K02288, tubastatin, TCS-HDAC6, tubacin, or combinations thereof.
In some embodiments, EC capillary regression and/or lymphatic tube regression can be rescued by a combination of pharmacologic agents and one or more antibodies. In some embodiments, EC capillary regression and/or lymphatic tube regression occurring in an infected patient (e.g., infected by SARS-CoV-2, influenza, or bacteria) can be rescued by a combination of pharmacologic agents and one or more antibodies. In some embodiments, EC capillary regression and/or lymphatic tube regression caused by an infection (e.g., a SARS-CoV-2, influenza, or bacterial infection) can be rescued by a combination of pharmacologic agents and one or more antibodies. In some embodiments, the one or more antibodies can include neutralizing antibodies. In some embodiments, the neutralizing antibodies can include antibodies directed to IL-1β, TNFα, IFNγ, IL-4, IL-13, or combinations thereof.
In some embodiments, the combination of pharmacologic agents can include an agent stimulating cyclic AMP levels, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include a p38 Map kinase inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include an HDAC inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include a GSK3β inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include an ALK inhibitor (e.g., ALK4, ALK5, ALK2, and/or ALK1 inhibitors), one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include an antagonistic recombinant protein (e.g., IL-1RA), one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include a Factor Xa inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include a protease activated receptor 1 (PAR1) inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof.
In some embodiments, the combination of pharmacologic agents can include an agent stimulating cyclic AMP levels, a p38 Map kinase inhibitor, an HDAC inhibitor, a GSK3β inhibitor, an ALK inhibitor, an antagonistic recombinant protein, a Factor Xa inhibitor, a PAR1 inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an ALK inhibitor, an antagonistic recombinant protein, a Factor Xa inhibitor, a PAR1 inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof.
In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an ALK inhibitor (e.g., ALK4, ALK5, ALK2, and/or ALK1 inhibitors), one or more antibodies (e.g., neutralizing antibodies), or combinations thereof. In some embodiments, the combination of pharmacologic agents can include an antagonistic recombinant protein (e.g., IL-1RA), one or more antibodies (e.g., neutralizing antibodies), or combinations thereof. In some embodiments, the combination of pharmacologic agents can include a Factor Xa inhibitor, one or more antibodies (e.g., neutralizing antibodies), or combinations thereof. In some embodiments, the combination of pharmacologic agents can include a protease activated receptor 1 (PAR1) inhibitor, one or more antibodies (e.g., neutralizing antibodies), or combinations thereof.
In some embodiments, the combination of pharmacologic agents can include an agent stimulating cyclic AMP levels, a p38 Map kinase inhibitor, an HDAC inhibitor, a GSK3β inhibitor, an ALK inhibitor, an antagonistic recombinant protein, a Factor Xa inhibitor, a PAR1 inhibitor, one or more antibodies (e.g., neutralizing antibodies), or combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FISTSB, an ALK inhibitor, an antagonistic recombinant protein, a Factor Xa inhibitor, a PAR1 inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof.
In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, SB431542, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, K02288, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, tubastatin, TCS-HDAC6, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, IL-1RA, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the combination of pharmacologic agents can include FIST, FIRSTSB, SB431542, K02288, tubastatin, TCS-HDAC6, IL-1RA, a Factor Xa inhibitor, a PAR1 inhibitor, one or more antibodies (e.g., neutralizing antibodies), or any combinations thereof. In some embodiments, the pharmacologic agents described herein or a pharmaceutical composition thereof can be administered to patient in need thereof by any accepted route of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal (e.g., intranasal), nasogastric, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral and vaginal.
In some embodiments, the pharmacologic agents are administered at a dose from about 1 mg/kg to about 100 mg/kg. In some embodiments, the pharmacologic agents are administered at a dose at about 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90 mg/kg, 95 mg/kg, 100 mg/kg, 150 mg/kg, or 200 mg/kg. In some embodiments, the dose is a therapeutically effective amount. In some embodiments, the pharmacologic agents can be administered on a daily basis (e.g., as a single dose or as two or more divided doses) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month). In some embodiments, the period of administration of the pharmacologic agents as described herein is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.
Further embodiments of the disclosure can be found in the attached Appendix A which is herein incorporated by reference in its entirety. The disclosure is further described in the following non-limiting examples.
Human umbilical vein endothelial cells (HUVECs) were from Lonza, human brain vascular pericytes from ScienCell and THP-1-Null cells from Invivogen. Culture media (e.g., Medium 199) were from Fisher Scientific and FCS was from Sigma. All biochemical reagents were from Tocris, except for Pam3CSK4 which were from Invivogen, phorbol ester from Sigma, and Huzzah KLA from Avanti-Polar Lipids. Neutralizing antibodies were from R&D Systems, and all Western blotting antibodies were from Cell Signaling Technology, except for acetylated tubulin antibodies from Millipore, and tubulin antibodies from Sigma.
ECs (passages 3-6) and pericytes (passages 3-12) were cultured as previously described49,50. THP-1 cells were cultured in RPMI-1640-20% FCS. THP-1-T macrophages were differentiated for 72 hr. with 50 ng/ml of phorbol ester in RPMI-20% FCS, and then treated for 48 hr. in RPMI-2% FCS prior to adding TLR ligands. THP-1-VT macrophages were induced to differentiate for 72 hr. with 10-7 M vitamin D3 (Calcitriol) in RPMI-20% FCS, followed by 48 hr. with phorbol ester in RPMI-2% FCS prior to adding TLR ligands.
Huzzah-KLA (i.e. LPS) or Pam3CSK4 were added to THP-1 cells in culture at a final concentration of 100 ng/ml in RPMI-1640 containing the RSII serum-free supplement. Conditioned media or total RNA were collected after 4 hr. RT-PCR primer sets:
ECs or ECs with pericytes were suspended in 3D collagen matrices and incubated at 37° C. in serum-free defined media as described9,50,51. Recombinant factors or THP-1 conditioned media were added at the indicated doses to existing 48 or 72 hr. cultures with EC only or EC-pericyte tube networks, respectively. After 24 or 48 hr. for EC only or EC-pericyte tubes, respectively, cultures were fixed in 3% glutaraldehyde or 3% paraformaldehyde. EC tube areas were traced and quantitated as described. In some cases, neutralizing antibodies were added (10 μg/ml). For signaling experiments, lysates were prepared from control vs. regressing 3D cultures at different time points.
Stained cultures were photographed using an inverted microscope and imaging software (Olympus) while time-lapse videomicroscopy of living cells was performed using a DMI6000B microscope (Leica) and MetaMorph software (Molecular Devices). Confocal images were taken using Leica SP8 LIGHTNING White light laser confocal laser scanning microscope using LAS software (Leica). LAS software and Fiji (Image J) were used to reconstruct confocal Z stacks and create rotating movies.
Statistical data analysis was performed using Microsoft Excel (Microsoft). Variances were obtained and student t tests were used to compare means between conditions while statistical significance was set at a minimum of p<0.05. All analyses were obtained using a minimum of n≥6 fields per experiment, and >3 validating experimental replicates in total. Unpaired, two-tailed t tests were performed for all statistical comparisons of hyaloid vessel numbers and measurements using GraphPad Prism 7.
Studies to define the factors and signals that promote endothelial cell (EC) lumen and tube formation, EC sprouting and EC-pericyte tube co-assembly have been performed under serum-free defined conditions so that the functional role of individual molecules that regulate these processes can be assessed. Disclosed herein, the factors that control capillary regression are defined. Capillary regression is a process that has been largely neglected despite the likelihood that it may present a fundamental pathogenic feature of major human diseases where capillary disassembly and regression are known to occur (i.e. hypertension, diabetes, ischemic disease in many tissues, neurodegenerative diseases, and malignant cancer). Screening of many factors to identify stimulators of EC tubulogenesis or sprouting, led to the discovery that IL-1β, IL-la, TNFα and thrombin (individually and their combinations) directly cause capillary tube collapse and regression (
Since IL-1 and TNF are known to be induced following macrophage exposure to toll-like receptor ligands, such as Pam3CSK4 and lipopolysaccharide (LPS), human macrophages were treated with these ligands to determine if capillary regression promoting activities could be detected. Neither Pam3CSK4 or LPS by themselves (with and without the presence of LPS-binding protein, LBP) had any ability to directly cause EC tube regression (
The potent pro-regressive activities within Pam3CSK4- or LPS-induced macrophage conditioned media were identified. Gene expression studies were performed to assess if Pam3CSK4 or LPS affected mRNA expression of inflammatory cytokines and demonstrated marked upregulation of TNFα, IL-1β, IL-la, IL-6 and IL-10 (i.e. an anti-inflammatory cytokine) as well as tissue factor (i.e. F3), which could lead to local thrombin production during a tissue injury response (
Pharmacologic inhibitors that would antagonize EC tube regression in response to pro-regressive factors were identified. After screening hundreds of combinations of inhibitors or agonists, a four-drug combination (i.e. FIST) was identified that completely rescued the pro-regressive influence of IL-1β, TNFα, and the pro-regressive macrophage media (
Identification of Additional Factors that Stimulate EC Tube Regression
As a part of the screening process to identify other factors that promote EC tube regression, inflammatory cytokines were also screened, including members of the IL-1 and TNF cytokine superfamilies as well as other growth factors known to impact the vasculature (
As described herein, macrophage conditioned medium could induce selective loss of EC-lined tubes, while sparing adjacent pericytes (
Signaling pathways that underlie the capillary regression process described herein were also evaluated. Lysates from control vs. regressing cultures in response to TNFα, IL-1β, TNFα+thrombin, and IL-1β+thrombin over a 24-hr. time course of regression were prepared and Western blot analyses were performed (
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
This application claims priority to U.S. Provisional Patent Application No. 62/915,932, filed on Oct. 16, 2019. The content of this application is incorporated by reference in its entirety.
This invention was made with government support under Grant No. HL128584, awarded by the National Institutes of Health. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/056077 | 10/16/2020 | WO |
Number | Date | Country | |
---|---|---|---|
62915932 | Oct 2019 | US |